High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients,
ABSTRACT INTRODUCTION: The treatment of patients with cystic fibrosis involves the use of ototoxic drugs, mainly aminoglycoside antibiotics. Due to the use of these drugs, fibrocystic patients are at risk of developing hearing loss. OBJECTIVE: To evaluate the hearing of patients with cystic fibr...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-12-01
|
Series: | Brazilian Journal of Otorhinolaryngology |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942015000600589&lng=en&tlng=en |
id |
doaj-2cbc0a19a4a34e8589c4d43b425bc54e |
---|---|
record_format |
Article |
spelling |
doaj-2cbc0a19a4a34e8589c4d43b425bc54e2021-03-02T09:48:34ZengElsevierBrazilian Journal of Otorhinolaryngology1808-86862015-12-0181658959710.1016/j.bjorl.2015.08.011S1808-86942015000600589High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients,Lucia Bencke GeyerSergio Saldanha Menna BarretoLiese Loureiro WeigertAdriane Ribeiro TeixeiraABSTRACT INTRODUCTION: The treatment of patients with cystic fibrosis involves the use of ototoxic drugs, mainly aminoglycoside antibiotics. Due to the use of these drugs, fibrocystic patients are at risk of developing hearing loss. OBJECTIVE: To evaluate the hearing of patients with cystic fibrosis by High Frequency Audiometry and Distortion Product Otoacoustic Emissions. METHODS: Cross-sectional study. The study group consisted of 39 patients (7-20 years of age) with cystic fibrosis and a control group of 36 individuals in the same age group without otologic complaints, with normal audiometric thresholds and type A tympanometric curves. High Frequency Audiometry and Distortion Product Otoacoustic Emissions tests were conducted. RESULTS: The study group had significantly higher thresholds at 250, 1000, 8000, 9000, 10,000, 12,500, and 16,000 Hz (p = 0.004) as well as higher prevalence of otoacoustic emission alterations at 1000 and 6000 Hz (p = 0.001), with significantly lower amplitudes at 1000, 1400, and 6000 Hz. There was a significant association between alterations in hearing thresholds in High Frequency Audiometry with the number of courses of aminoglycosides administered (p = 0.005). Eighty-three percent of patients who completed more than ten courses of aminoglycosides had hearing loss in High Frequency Audiometry. CONCLUSION: A significant number of patients with cystic fibrosis who received repeated courses of aminoglycosides showed alterations in High Frequency Audiometry and Distortion Product Otoacoustic Emissions. The implementation of ten or more aminoglycoside cycles was associated with alterations in High Frequency Audiometry.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942015000600589&lng=en&tlng=enFibrose císticaAminoglicosídeosAudiometria |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lucia Bencke Geyer Sergio Saldanha Menna Barreto Liese Loureiro Weigert Adriane Ribeiro Teixeira |
spellingShingle |
Lucia Bencke Geyer Sergio Saldanha Menna Barreto Liese Loureiro Weigert Adriane Ribeiro Teixeira High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients, Brazilian Journal of Otorhinolaryngology Fibrose cística Aminoglicosídeos Audiometria |
author_facet |
Lucia Bencke Geyer Sergio Saldanha Menna Barreto Liese Loureiro Weigert Adriane Ribeiro Teixeira |
author_sort |
Lucia Bencke Geyer |
title |
High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients, |
title_short |
High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients, |
title_full |
High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients, |
title_fullStr |
High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients, |
title_full_unstemmed |
High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients, |
title_sort |
high frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients, |
publisher |
Elsevier |
series |
Brazilian Journal of Otorhinolaryngology |
issn |
1808-8686 |
publishDate |
2015-12-01 |
description |
ABSTRACT INTRODUCTION: The treatment of patients with cystic fibrosis involves the use of ototoxic drugs, mainly aminoglycoside antibiotics. Due to the use of these drugs, fibrocystic patients are at risk of developing hearing loss. OBJECTIVE: To evaluate the hearing of patients with cystic fibrosis by High Frequency Audiometry and Distortion Product Otoacoustic Emissions. METHODS: Cross-sectional study. The study group consisted of 39 patients (7-20 years of age) with cystic fibrosis and a control group of 36 individuals in the same age group without otologic complaints, with normal audiometric thresholds and type A tympanometric curves. High Frequency Audiometry and Distortion Product Otoacoustic Emissions tests were conducted. RESULTS: The study group had significantly higher thresholds at 250, 1000, 8000, 9000, 10,000, 12,500, and 16,000 Hz (p = 0.004) as well as higher prevalence of otoacoustic emission alterations at 1000 and 6000 Hz (p = 0.001), with significantly lower amplitudes at 1000, 1400, and 6000 Hz. There was a significant association between alterations in hearing thresholds in High Frequency Audiometry with the number of courses of aminoglycosides administered (p = 0.005). Eighty-three percent of patients who completed more than ten courses of aminoglycosides had hearing loss in High Frequency Audiometry. CONCLUSION: A significant number of patients with cystic fibrosis who received repeated courses of aminoglycosides showed alterations in High Frequency Audiometry and Distortion Product Otoacoustic Emissions. The implementation of ten or more aminoglycoside cycles was associated with alterations in High Frequency Audiometry. |
topic |
Fibrose cística Aminoglicosídeos Audiometria |
url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942015000600589&lng=en&tlng=en |
work_keys_str_mv |
AT luciabenckegeyer highfrequencyhearingthresholdsandproductdistortionotoacousticemissionsincysticfibrosispatients AT sergiosaldanhamennabarreto highfrequencyhearingthresholdsandproductdistortionotoacousticemissionsincysticfibrosispatients AT lieseloureiroweigert highfrequencyhearingthresholdsandproductdistortionotoacousticemissionsincysticfibrosispatients AT adrianeribeiroteixeira highfrequencyhearingthresholdsandproductdistortionotoacousticemissionsincysticfibrosispatients |
_version_ |
1724238435217047552 |